AstraZeneca to supply 400 million of potential vaccine to Europe

▴ astrazeneca-supply-400-million-potential-vaccine-europe
Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon

UK Pharma company AstraZeneca Plc has come in a contract with European governments to provide its potential vaccine against the Coronavirus to assist combat the pandemic.
The contract is for up to 400 million doses of the vaccine, developed by the University of Oxford, the company reportedly said on Saturday, adding that it had been looking to expand the manufacturing of the vaccine, which it said it might provide for no profit during the pandemic. The vaccine remains in clinical trials. If the trial results convince regulators the vaccine is safe and effective, deliveries would be expected to start out by 2020 end.
The deal thus inscribes that Europe's Inclusive Vaccines Alliance (IVA), a group formed by France, Germany, Italy, and also the Netherlands to secure vaccine doses for all its member States soon.

"This will make sure that hundreds of millions of people in Europe will have access to the present vaccine, in fact, if it works and that we will know that by summer-end," the company's chief executive, Pascal Soriot was quoted as saying to the journalists. He said he has "good hope" that it'll work, supported initial data.
The alliance "will work alongside the European Commission and other countries in Europe to make sure everybody across Europe is provided with the vaccine," he said.
"We have a really self-sufficient supply chain for Europe" with manufacturers lined up within the Netherlands, Germany, Italy, and Italy, among others, he further said.


The vaccines are for all EU member states. The four nations that agreed the deal can pay for the entire amount, which has not been disclosed, and therefore the scheme allows other countries to hitch it under equivalent conditions, a source from the Italian health ministry said.
Apparently, China, Brazil, Japan, and Russia have also shown interest in this vaccine.
It has got the green signal from The British Medicines and Healthcare products regulatory authority (MHRA) kick start the phase III clinical trial of the vaccine after studies suggest sufficient efficacy and safety, Soriot reportedly said.
At a gathering of EU Health Ministers on Friday, IVA apparently agreed to merge its activities with those of the EU Commission, Germany's Health Ministry said.
It has agreed on the manufacturing of manufacturing 2 billion doses of the vaccine to serve its target beneficiaries along with two Bill Gates-backed ventures and a $1.2 billion agreement with the United States government.
The deal will add an extra 100 million doses to the two billion already committed by the group, AstraZeneca said.
There are not any approved vaccines or treatments for COVID-19, the highly contagious respiratory disease caused by the novel coronavirus.
"Many countries within the world have already secured vaccines, Europe has not yet. The rapid coordinated action of a gaggle of member states will create added value for all EU citizens during this crisis," Italian Health Minister Roberto Speranza was quoted as saying

Tags : #Coronavirus #Vaccine #Astrazeneca #Europe #China #Brazil #BillGates

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Ethics of Live Surgery Broadcasts: NMC Seeks Public OpinionMay 17, 2024
Successful Removal of 3.7 KG Large Abdominal Tumor from 14-Year-Old Somalian Girl at KIMS Cuddles HospitalMay 16, 2024
iLEAD Sets a Precedent by Launching a Graphic Anthology Authored by Multimedia, Animation and Graphics Students May 16, 2024
Ramaiah Memorial Hospital Launches Novel Intra-Operative Radiation Therapy (IORT); Achieves significant advancement in Cancer Treatment to Enhance Quality of LifeMay 16, 2024
IIITH Announces Product Management Summer SchoolMay 16, 2024
Çelebi India's Delhi Cargo Terminal Successfully Handles Airbus H125 Helicopter ShipmentMay 16, 2024
Plant-Based Diets and Prostate Cancer: New UCSF Study Shows Promising ResultsMay 16, 2024
National Medical Commission Approves 112 New Medical CollegesMay 16, 2024
Study Suggests That Chemotherapy Results in Physical Decline for Older Women with Breast CancerMay 16, 2024
Google DeepMind's AlphaFold 3: Revolutionizing Drug Discovery with AIMay 16, 2024
Hester Biosciences Ltd reports Consolidated Revenue growth of 18% at Rs. 79.3 crore, EBITDA up 37% to Rs. 16.4 crore and Net Profit up 12% to Rs. 6.40 crore in Q4FY24May 16, 2024
Akshay Tritiya Parna Mahotsav heldMay 16, 2024
IT Minister Sridhar Babu to grace the 10th National Facilities Managers Summit-2024, to be held in the cityMay 15, 2024
Alarming Study Reveals Cancer-Causing Chemicals in Car InteriorsMay 15, 2024
India's Thalassemia Challenge: The Importance of Early Screening and TreatmentMay 15, 2024
The Dangers of Ultra-Processed Foods: A 30-Year Study Raises AlarmsMay 15, 2024
Unique Genetic Risk Factors for Breast Cancer Found in African Ancestry StudyMay 15, 2024
AsiaMedic partners with Sunway to establish new diagnostic imaging centreMay 14, 2024
Kamineni Doctors Successfully Remove Bone Stuck Near Heart in Elderly PatientMay 14, 2024
On International Nurses Day, American Oncology Institute (AOI) launches #TheExtraordinaryCareGiver Campaign as Tribute to Oncology NursesMay 14, 2024